• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

作者信息

Cornely Oliver A, Robertson Michael N, Haider Shariq, Grigg Andrew, Geddes Michelle, Aoun Mickael, Heinz Werner J, Raad Issam, Schanz Urs, Meyer Ralf G, Hammond Sarah P, Mullane Kathleen M, Ostermann Helmut, Ullmann Andrew J, Zimmerli Stefan, Van Iersel M L P S, Hepler Deborah A, Waskin Hetty, Kartsonis Nicholas A, Maertens Johan

出版信息

J Antimicrob Chemother. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382.

DOI:10.1093/jac/dkx382
PMID:29029280
Abstract
摘要

相似文献

1
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.静脉注射泊沙康唑用于侵袭性真菌病风险患者的3期随机、开放标签研究的药代动力学和安全性结果。
J Antimicrob Chemother. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382.
2
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.来自一项 3 期随机、开放性、研究的药代动力学和安全性结果，研究了静脉用泊沙康唑在有侵袭性真菌感染风险的患者中的应用。
J Antimicrob Chemother. 2017 Dec 1;72(12):3406-3413. doi: 10.1093/jac/dkx263.
3
Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.中性粒细胞减少症儿童泊沙康唑静脉溶液和口服混悬剂的药代动力学和安全性：一项开放标签、序贯剂量递增试验。
Int J Antimicrob Agents. 2020 Sep;56(3):106084. doi: 10.1016/j.ijantimicag.2020.106084. Epub 2020 Jul 17.
4
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.泊沙康唑静脉溶液在侵袭性真菌病高危患者中的药代动力学及安全性1B期研究。
Antimicrob Agents Chemother. 2014 Jul;58(7):3610-7. doi: 10.1128/AAC.02686-13. Epub 2014 Apr 14.
5
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.泊沙康唑片剂在侵袭性真菌病高危患者中的3期药代动力学和安全性研究。
J Antimicrob Chemother. 2016 Mar;71(3):718-26. doi: 10.1093/jac/dkv380. Epub 2015 Nov 26.
6
Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.泊沙康唑片剂制剂在有侵袭性真菌感染高危风险的中国参与者中的药代动力学和安全性。
Adv Ther. 2020 May;37(5):2493-2506. doi: 10.1007/s12325-020-01341-x. Epub 2020 Apr 22.
7
Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.口服泊沙康唑在患有移植物抗宿主病的异基因造血干细胞移植受者中的药代动力学。
Pharmacotherapy. 2007 Dec;27(12):1627-36. doi: 10.1592/phco.27.12.1627.
8
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.通过对343个疗程的分析，对泊沙康唑新片剂和静脉制剂预防侵袭性真菌感染的安全性和有效性进行实际评估
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00188-17. Print 2017 Aug.
9
A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy.一项多中心、开放性研究，评估泊沙康唑口服混悬液治疗对一线治疗无效或不耐受的侵袭性真菌感染患者的疗效。
Future Microbiol. 2012 Feb;7(2):201-9. doi: 10.2217/fmb.11.158.
10
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.长期口服泊沙康唑治疗难治性侵袭性真菌感染的安全性。
Clin Infect Dis. 2006 Jun 15;42(12):1726-34. doi: 10.1086/504328. Epub 2006 May 8.

引用本文的文献

1
Posaconazole for Prevention of COVID-19-Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case-Control Study (POSACOVID).泊沙康唑预防机械通气患者新型冠状病毒肺炎相关肺曲霉病：一项欧洲多中心病例对照研究（POSACOVID）
Mycoses. 2025 Jan;68(1):e70023. doi: 10.1111/myc.70023.
2
Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids.评估奥替康唑和其他两种四氮唑类抗真菌药抑制肾上腺类固醇生成及皮质类固醇外周代谢的潜在风险。
Front Pharmacol. 2024 Aug 8;15:1394846. doi: 10.3389/fphar.2024.1394846. eCollection 2024.
3
From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis.
从孢子到解决方案：关于毛霉病的全面叙述性综述
Diagnostics (Basel). 2024 Jan 31;14(3):314. doi: 10.3390/diagnostics14030314.
4
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).血液恶性肿瘤患者侵袭性真菌病的一级预防：德国血液学和肿瘤内科学会（DGHO）传染病工作组（AGIHO）的建议 2022 年更新版。
J Antimicrob Chemother. 2023 Aug 2;78(8):1813-1826. doi: 10.1093/jac/dkad143.
5
Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing.基于真实世界治疗药物监测数据的泊沙康唑片和混悬液在接受静脉和口服给药的住院患儿体内生物利用度的模型估算。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0007723. doi: 10.1128/aac.00077-23. Epub 2023 Jun 1.
6
Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats.建立 UPLC-MS/MS 法研究达沙替尼与泊沙康唑在大鼠体内的药代动力学相互作用。
Drug Des Devel Ther. 2021 May 24;15:2171-2178. doi: 10.2147/DDDT.S301241. eCollection 2021.
7
Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.健康中国受试者中泊沙康唑静脉注射液和口服片剂的药代动力学和安全性，以及食物对片剂生物利用度的影响。
Clin Drug Investig. 2019 Nov;39(11):1109-1116. doi: 10.1007/s40261-019-00833-1.
8
A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.泊沙康唑固体口服制剂的群体药代动力学模型。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.02465-17. Print 2018 Jul.